RxDoctor Payments Data

Derek Fritz

Family Medicine · Clarion, PANPI 1982264305

Payments from drug & device makers

$2,558in general payments, 2019–2025

Across 154 payments — averaging $16.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$480
  • Pfizer$414
  • Amgen$258
  • Lilly USA, LLC$232
  • AbbVie$229
  • AstraZeneca$159
  • plus $786 from 21 others

What the payments were for

  • Food & beverage$2,558100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,558 in reported general payments places this provider in the 80th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$213,521
Medicare patients
354
Services billed
7,956

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide56$69,037
JardianceEmpagliflozin47$59,707
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$26,757
TrulicityDulaglutide18$22,976
EliquisApixaban30$20,175
MounjaroTirzepatide12$16,657
Gabapentin158$2,359
Desvenlafaxine Succinate ErDesvenlafaxine Succinate16$2,036
Duloxetine Hcl60$1,956
Levothyroxine Sodium167$1,764
Albuterol Sulfate HfaAlbuterol Sulfate49$1,664
Lisinopril230$1,658
Ventolin HfaAlbuterol Sulfate24$1,611
Omeprazole111$1,543
Atorvastatin Calcium181$1,385

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$480$69,03756 claims
Boehringer IngelheimJardiance$44$59,70747 claims
Lilly USA, LLCTrulicity, Mounjaro$232$39,63230 claims
GSKTrelegy Ellipta$142$26,75737 claims
PfizerEliquis$414$20,17530 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$29$1,764167 claims
AbbVieSynthroid$229$50312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Clarion

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →